Volume 4; Number 5 May 2010
|
|
- Lydia Webb
- 5 years ago
- Views:
Transcription
1 Volume 4; Number 5 May 2010 CLINICAL GUIDELINES FOR ANTIDEPRESSANT USE IN PRIMARY AND SECONDARY CARE Lincolnshire Partnership Foundation Trust in conjunction with Lincolnshire PACEF have recently updated and expanded local guidance on the use of antidepressant drugs for the treatment of depression. This revision was necessitated by the publication of NICE Clinical Guidelines 90 and 91: Depression - Treatment and management of depression in adults, including adults with a chronic physical health problem (October 2009). It is the purpose of this special edition of the PACE Bulletin to summarize the key points of local guidance and the NICE Clinical Guidelines with particular relevance to the management of depression in primary care. The full text LPFT document can be accessed in the PACEF section of Treatment of Mild Depression in Primary Care Antidepressant medication is not recommended for the initial treatment of mild symptoms of depression. The risks of antidepressant drugs are well documented and the benefits in mild depression unsubstantiated; randomised controlled trial evidence indicates little difference in outcome between antidepressant medication and placebo. Antidepressants should be considered for patients with mild depression that persists after other interventions have failed, in those whose depression is associated with psychosocial and medical problems and when those with a past history of moderate or severe depression present with mild depression. Many patients with mild depression respond to interventions such as exercise or guided self-help; many improve while being monitored without any additional help (so-called active monitoring ). More structured therapies, such as problem-solving, brief cognitive behavioural therapy (CBT) or counselling can be helpful. Treatment of Moderate or Severe Depression in Primary Care Antidepressant treatment should be considered for people with: Sub-threshold depressive symptoms present for at least 2 years. Sub-threshold depressive symptoms or mild depression persisting after other interventions. Mild depression that complicates the care of a chronic physical health problem. Moderate depression. A chronic physical health problem and presenting with moderate depression, after other interventions have been attempted or rejected by the person. A past history of severe depression or presenting with severe depression. Antidepressant Selection: First Line There is more evidence for the effectiveness of antidepressant medication in the treatment of moderate to severe depression. Antidepressants have been shown to be as effective as psychological interventions, are widely available and cost less. 1
2 In the primary care setting, there appears to be little difference in terms of efficacy between different antidepressant drugs; there are, however, differences in terms of side effect profile, potential for interactions and safety in overdose which will necessitate some degree of tailoring of therapy to the individual patient. NICE Clinical Guidelines 90 and 91 advocate fluoxetine, citalopram or sertraline as preferred first line antidepressant choices. SSRIs are favoured first line because they are as effective as other antidepressants, better tolerated than many, less cardiotoxic, safer in overdose and generally less expensive (with the exception of escitalopram). Dose titration is not routinely required, so inadvertent prescribing of sub-therapeutic doses is less likely to occur. In co-morbid depression with anxiety, generic citalopram is the preferred alternative. Citalopram and fluoxetine are also preferred in patients at risk of self-harm. Citalopram should be used with caution (and preferably avoided) in patients with established cardiac disease that may increase the risk of ventricular arrhythmias (e.g. recent MI). Of the generic SSRIs, sertraline has evidence of superior tolerability and is also the preferred agent in people with ischaemic heart disease (e.g. post MI, unstable angina). People receiving antidepressant treatment for a first episode presentation should be advised to continue medication for a minimum of 6 months after remission or for 2 years or more in those at a risk of relapse. People who have had two or more depressive episodes in the recent past and who have experienced significant functional impairment during the episodes should be advised to continue treatment for at least 2 years. Under no circumstances should a sub-therapeutic dose of an antidepressant be used to treat depression: a diagnosis of mild depression does not necessitate pharmacological intervention in most instances; in moderate to severe depression a full course of an appropriate agent, prescribed at a treatment dose is indicated. The Medicines and Healthcare products Regulatory Agency (MHRA) / Committee on Safety of Medicines (CSM) Expert Working Group on SSRIs recommended that SSRIs should be prescribed at the lowest possible therapeutic dose (fluoxetine 20mg once daily; citalopram 20mg once daily). Patients should be monitored closely in the early stages of treatment for restlessness, agitation and suicidality (particularly if the patient is below 30). Doses should be tapered gradually on stopping. Patients should be given appropriate information on the nature, course and treatment of depression, including the use and likely side effects of medication (particularly akathesia, increased anxiety, increased agitation), the possibility of discontinuation/withdrawal symptoms and potential interactions with concomitant medicines or physical illness. Patients should be advised of the time lag for antidepressants to start working effectively. Patients should be reminded of the importance of taking the treatment as prescribed. Poor patient concordance is a significant contributor to treatment failure. Compliance rates of between 40% and 90% (mean 65%) have been recorded in different studies. It is recommended that all patients initiated on an antidepressant should be reviewed after the first 2-4 weeks of treatment in order to assess tolerance and concordance. The initial antidepressant should be monitored for response over 3-4 weeks. If no response is seen, increasing dose or switching antidepressant should be considered. If a partial response is seen, continue treatment for a further 2-4 weeks and reassess. When switching of antidepressants becomes necessary, refer to the table on Appendix 1 for guidance. Do not prescribe or advise the use of St John s Wort for depression. Different preparations tend to vary in potency and there is significant potential for serious interactions with other drugs including oral contraceptives, anticoagulants and anticonvulsants. 2
3 Antidepressant Selection: Second Line Potential second line agents include: other SSRIs (such as escitalopram), TCAs (particularly lofepramine), mirtazepine, venlafaxine (below 300mg), trazodone and moclobemide. Escitalopram is the s-enantiomer of citalopram. It is at least as effective as other SSRIs and marginally better tolerated (except for sertraline). The evidence for the clinical superiority of escitalopram is limited to the treatment of severe depression; any clinical advantage must be balanced against the higher cost of escitalopram when compared to alternative generic SSRIs. Escitalopram may be considered second line for people with severe depression who have shown an antidepressant response to other SSRIs but have been unable to tolerate side-effects. It should not be used first line or to treat people who have failed to respond to other SSRIs. Mirtazapine is a potentially useful second line agent when first-line SSRIs have failed to induce an adequate response or are poorly tolerated. It is also useful in the augmentation of other antidepressants in treatment-resistant depression (although trial evidence is limited). Other potential roles are in patients with depression with co-existing anxiety or sleep disturbance and those with prostatism, glaucoma, poorly controlled epilepsy, or diabetes. Lofepramine remains the best tolerated and safest tricyclic antidepressant and should be prescribed as the tricyclic of choice where a tricyclic is indicated (e.g. when sedation is required). NICE recommend that people should not be switched to, or started on, dosulepin because evidence supporting its tolerability relative to other antidepressants is outweighed by the increased cardiac risk and toxicity in overdose. Amitriptyline should not be initiated routinely in depression because of similar concerns over increased cardiac risk and toxicity in overdose. The degree of sedation associated with TCAs varies from agent to agent, with imipramine, lofepramine and nortriptyline being less sedative than other options. Earlier restrictions on venlafaxine use have been partially reversed. Current evidence suggests that venlafaxine is probably not cardiotoxic. However, it is associated with a greater risk of death in overdose than other equally effective antidepressants recommended in primary care. Venlafaxine, moclobemide and lofepramine should be used with caution (and preferably avoided) in patients with established cardiac disease that may increase the risk of ventricular arrhythmias (e.g. recent MI). Antidepressant Selection: Third Line Third line agents that should only be initiated by a mental health specialist include: paroxetine, fluvoxamine, reboxetine, duloxetine, phenelzine, isocarboxazid, tranylcypramine, mianserin, agomelatine, flupenthixol, tryptophan, venlafaxine (above 300mg) and lithium. High dose venlafaxine remains contraindicated in patients with an identified very high risk of serious cardiac ventricular arrhythmia (e.g. those with a significant left ventricular dysfunction (NYHA Class III/IV)) and in patients with uncontrolled hypertension. Venlafaxine is no longer contra-indicated in patients with electrolyte imbalance. Duloxetine (Cymbalta) is promoted as an alternative Selective Serotonin and Noradrenaline Reuptake Inhibitor (SNRI) to venlafaxine without QTc complex prolongation, or need for BP monitoring in patients without pre-existing hypertension. However, due to the lack of long-term efficacy and safety data, PACEF strongly recommend initiation by specialists only. Prescribers are reminded that duloxetine is a black triangle drug and that all suspected 3
4 adverse drug reactions must be reported via the MHRA Yellow Card scheme. Duloxetine (Cymbalta) is designated. Paroxetine is associated with a higher incidence of sweating, sedation and sexual dysfunction than other SSRIs and with significantly more problems on discontinuation. It has a number of potential drug-drug interactions, due to its effect on hepatic enzymes. It should not be used in patients taking atomoxetine. Paroxetine retains a role in the treatment of some anxiety disorders. Fluvoxamine is associated with a higher incidence of nausea than other SSRIs. It interacts significantly with a number of other drugs including clozapine, due to an effect on hepatic enzymes. It is not widely prescribed. Fluvoxamine should be avoided in patients taking theophylline, clozapine, methadone or tizanidine. Reboxetine is a relatively selective noradrenaline reuptake inhibitor (NARI). It is not licensed for use in older adults. The Cipriani meta-analysis of head-to-head trials of antidepressants was unfavourable to reboxetine in terms of both response rate and tolerability. Summary of PACEF Decisions: Antidepressants Drug Indication(s) Traffic Light Status First line Citalopram tablets (generic) Depressive illness in the initial phase and as maintenance therapy against potential relapse or recurrence. First line option Fluoxetine capsules (generic) Major depression First line option Sertraline tablets (generic) Depression First line option Second Line Clomipramine capsules (generic) Depressive illness Escitalopram tablets (Cipralex) Depression Imipramine tablets (generic) Depressive illness Lofepramine tablets (generic) Depressive illness ; preferred TCA. Mirtazepine tablets (generic) Depressive illness Moclobemide tablets (generic) Major depression ; preferably avoid in those with established cardiac disease. Nortriptyline tablets (Allegron) Depressive illness Other indications are approved (e.g. neuropathic pain). Trazodone capsules/tablets (generic) Venlafaxine tablets (Efexor)/ modified release capsules (Efexor XL) Depressive illness, particularly where sedation is required Major depressive disorder; prevention of relapse or recurrence of depression, depression with anxiety. ; preferably avoid in those with established cardiac disease. Third Line Agomelatine tablets (Valdoxan) Major depression RED For use within LPFT only Amitriptyline tablets Depressive illness for depression Not recommended for the routine treatment of depression due to high rate of fatality in overdose. Other indications are approved (e.g. neuropathic 4
5 pain). Duloxetine capsules (Cymbalta) Depression Fluvoxamine tablets Depressive illness Isocarboxazid tablest Depressive illness Mianserin tablets Depressive illness, particularly where sedation is required Paroxetine tablets Major depression Phenelzine tablets (Nardil) Depressive illness Reboxetine tablets (Edronax) Major depression Tranylcypromine tablets Depressive illness Tryptophan tablets (Optimax) Venlafaxine tablets (Efexor) Venlafaxine tablets (Efexor)/ modified release capsules (Efexor XL) Not Recommended Dosulepin capsules/tablets (generic/all brands) An adjunctive therapy for depression resistant to standard antidepressants. Severely depressed or hospitalized patients who require doses of 300mg daily or above. Depression necessitating concurrent SSRI and venlafaxine treatment Depression; anxiety associated with depression as an adjunct Should only be initiated under specialist supervision Should only be initiated under specialist supervision RED-RED Not recommended for the treatment of depression due to high rate of fatality in overdose. St Johns Wort preparations Depression RED-RED St John s Wort preparations should not be prescribed or recommended for purchase due to variation in potency between different preparations and the serious risk of interaction with other medication. Appendix 1 Guidance on the switching of antidepressants The following table includes switches likely to be prescribed in general practice. From: To: TCA Citalopram Escitalopram Sertraline TCA 7d Citalopram Escitalopram Sertraline start drug 2 at half usual dose Fluoxetine Trazodone Moclobemide Venlafaxine Duloxetine Mirtazapine start drug 2 at half usual dose Stop SSRI first 7d (14d if sertraline) Fluoxetine 4-7d 4-7d 4-7d 5 week washout Trazodone W W 7d starting at 37.5mg Start venlafaxine at 37.5mg, increase slowly W Start venlafaxine at 37.5mg, increase slowly Start venlafaxine at 37.5mg or Stop SSRI and start duloxetine 60mg daily or Stop SSRI and start duloxetine 60mg daily Moclobemide 1d 1d 1d 1d 1d 1d 1d 4-7d W 5
6 Venlafaxine start drug 2 at half usual dose start drug 2 at half usual dose 7d W Duloxetine 1d 1d 1d 7d 1d 1d Mirtazapine W W W W 7d W Key : Careful cross-taper, start drug 2 at a low dose W: drug 1 before starting drug 2, no washout period required #d: Allow for a washout period of # days after stopping drug 1 before starting drug 2 at a low dose. References Anderson IM et al Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association of Psychopharmacology guidelines. Journal of Psychopharmacology 2008; 22(4): Cipriani A et al., Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis, Lancet 2009; 373: Lincolnshire Partnership NHS Foundation Trust, Guidance relating to the use of Antidepressant Medicines in Primary and Secondary Care (February 2010). NICE Clinical Guideline 90. Depression in adults (update) (October 2009) NICE Clinical Guideline 91. Depression in adults with a chronic physical health problem (October 2009) Acknowledgements Many thanks to Stephen Jones, Principal Pharmacist, Lincolnshire Partnership Foundation Trust for his detailed input into this edition of the PACE Bulletin. Stephen Gibson, Head of Prescribing and Medicines Management, NHS Lincolnshire May
Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services
Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services DEPRESSION Pharmacological Treatment of Depression NICE guidelines suggest the following stepped care model also
More informationAntidepressant Treatment of Depression
Antidepressant Treatment of Depression PLEASE REFER TO INTEGRATED CARE PATHWAY FOR INFORMATION RELATING TO THE OVERALL MANAGEMENT OF DEPRESSION SSRI s are first choice agents because they are as effective
More informationGuidelines on Choice and Selection of Antidepressants for the Management of Depression
Guidelines on Choice and Selection of Antidepressants for the Management of Depression 1. Introduction This guidance should be considered as part of a stepped care approach in the management of depressive
More informationGuidelines on Choice and Selection of Antidepressants for the Management of Depression
Working in partnership: Hertfordshire Partnership University NHS Foundation Trust East and North Hertfordshire Clinical Commissioning Group Herts Valleys Clinical Commissioning Group Guidelines on Choice
More informationGREATER MANCHESTER INTERFACE PRESCRIBING GROUP
GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationDepression: management of depression in primary and secondary care
Issue date: December 2004, with amendments April 2007 Quick reference guide (amended) Depression: management of depression in primary and secondary care Amendment of recommendations concerning venlafaxine:
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationAppendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)
Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Introduction / Background Treatment comes after diagnosis Diagnosis is based on
More information4.3 Antidepressants (ADDs) BNF Section 4.3
4.3 Antidepressants (ADDs) BNF Section 4.3 The aim of this guidance is to provide prescribing guidance and highlight good practice. It is not intended to be a comprehensive practice treatment guideline.
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationMedication management of anxiety & depression. Dr Katie Simpson GP Mental health lead East Berks CCG
Medication management of anxiety & depression Dr Katie impson GP Mental health lead East Berks CCG NICE guidelines for Anxiety tepped Care RIs and NRIs in Anxiety disorders RI ertraline Citalopram Fluoxetine
More informationDocument Title Pharmacological Management of Generalised Anxiety Disorder
Document Title Pharmacological Management of Generalised Anxiety Disorder Document Description Document Type Policy Service Application Trust Wide Version 1.1 Policy Reference no. POL 201 Lead Author(s)
More informationMMG004 GUIDELINES FOR THE USE OF HIGH DOSE VENLAFAXINE AND THE COMBINATION OF VENLAFAXINE AND MIRTAZAPINE IN THE TREATMENT OF DEPRESSION
MMG004 GUIDELINES FOR THE USE OF HIGH DOSE VENLAFAXINE AND THE COMBINATION OF VENLAFAXINE AND MIRTAZAPINE IN THE TREATMENT OF DEPRESSION Page 1 of 13 Table of Contents Why we need this Guideline... 3 What
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationGuidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 3 October 2014)
Guidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 3 October 2014) Date of Preparation: September 2014 Date for next full
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize
More informationPharmacotherapy of depression
Pharmacotherapy of depression Stuff you already know Stuff you probably know Stuff you possibly don t know Stuff you thought you knew but are mistaken about How long does it take for antidepressants
More informationThis initial discovery led to the creation of two classes of first generation antidepressants:
Antidepressants - TCAs, MAOIs, SSRIs & SNRIs First generation antidepressants TCAs and MAOIs The discovery of antidepressants could be described as a lucky accident. During the 1950s, while carrying out
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationQuick Guide to Common Antidepressants-Adults
Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa
More informationClinical guideline Published: 28 October 2009 nice.org.uk/guidance/cg91
Depression in adults with a chronic physical health problem: recognition and management Clinical guideline Published: 28 October 2009 nice.org.uk/guidance/cg91 NICE 2018. All rights reserved. Subject to
More informationGuidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 4.
Guidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 4.1 December 2018) Date of Preparation: January 2018 (with addition of
More informationDepression in Pregnancy
TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care Rebecca D. Lewis, DO OOA Summer CME Oklahoma City, OK 6 August 2017 Objectives Understand the epidemiology of depression. Recognize factors to help choose antidepressants.
More informationSupplementary Online Content
Supplementary Online Content Renoux C, Vahey S, Dell Aniello S, Boivin J-F. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol. Published
More informationReviews/Evaluations. Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients. Pharmacotherapeutic Options
Reviews/Evaluations Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients Childhood major depressive disorder (MDD) has become recognized as a serious and common illness affecting between
More informationAntidepressants Choosing the Right One
Antidepressants Choosing the Right One Dr Lim Boon Leng Consultant Psychiatrist Dr BL Lim Centre For Psychological Wellness #09-09, Gleneagles Medical Centre, 6 Napier Rd, S258499 www.psywellness.com.sg
More informationDepression: selective serotonin reuptake inhibitors
Depression: selective serotonin reuptake inhibitors Selective serotonin reuptake inhibitors (SSRIs) are considered first-line treatment for the majority of patients with depression. citalopram and fluoxetine
More informationPerinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs
Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs (Version 3 January 2015) Principal Author: Dr Jenny Cooke Consultant Psychiatrist, Brighton & Hove Perinatal Mental Health Service
More informationPregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)
Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned
More informationAnti-Depressant Medications
Anti-Depressant Medications A Introduction: This topic may be a little bit underestimated here in Jordan, while in western countries it has more significance. The function of anti-depressants is to change
More informationDepression in adults: treatment and management
1 2 3 4 Depression in adults: treatment and management 5 6 7 8 Appendix V3: recommendations that have been deleted of changed from 2009 guideline Depression in adults: Appendix V3 1 of 22 1 Recommendations
More informationCommon Antidepressant Medications for Adults
(and Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Fluoxetine Weekly (Prozac Weekly) 20 in AM w/ food (10 mg in elderly or those w/ panic disorder) 20 40 40 (If age >60yo, max 20) 10 10
More information- how many anti-depressant pills were prescribed to patients in years 2011/12/13
NHS Wet Kent Clinical Commiioning Group Our Ref: FOI.14.WK0196 RE: FREEDOM OF INFORMATION REQUEST Thank you for your requet for information under the Freedom of Information Act 2000 received on 25 February
More informationDISEASES AND DISORDERS
DISEASES AND DISORDERS 13. The mood (affective) disorders 99 14. The psychotic disorders: schizophrenia 105 15. The anxiety and somatoform disorders 111 16. Dementia and delirium 117 17. Alcohol and substance-related
More informationBRIEF SUMMARY CONTENT
Page 1 of 17 Brief Summary GUIDELINE TITLE Depression. The treatment and management of depression in adults. BIBLIOGRAPHIC SOURCE(S) National Collaborating Centre for Mental Health. Depression. The treatment
More informationClinical Guideline / Formulary Document Pharmacy Department Medicines Management Services
Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services ANXIETY DISORDERS This guideline covers a range of anxiety disorders, including generalised anxiety disorder, social
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationHazard ratio for coronary heart disease mortality for SMI patients versus controls (18-49 yrs) Hazard ratio for stroke
By Michael Dixon Contents Background to Bipolar Disorder and cardiac risk Mood stabilisers and cardiac risk factors Background to Depression and cardiac risk Antidepressants and cardiac risk factors Any
More informationAntidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry
Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free
More informationScottish Medicines Consortium
Scottish Medicines Consortium escitalopram, 5mg, 10mg, and 20mg tablets and 10mg/ml oral drops (Cipralex) No. (406/07) Lundbeck Ltd 7 September 2007 The Scottish Medicines Consortium has completed its
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationPharmacological Treatment of Anxiety & Depressive Disorders
Pharmacological Treatment of Anxiety & Depressive Disorders Dr Gary Jackson (MB BCh FRCPsych) Consultant Psychiatrist The Priory Hospital Chelmsford Wellesley Hospital Southend-on-Sea Medical Secretary:
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine
More informationSmoking Cessation Pharmacotherapy Guidelines
Smoking Cessation Pharmacotherapy Guidelines INTRODUCTION This guideline is based on public health guidance 10 Smoking Cessation Services issued by the National Institute for Health and Clinical Excellence
More informationPHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationHow to Manage Anxiety
How to Manage Anxiety Dr Tony Fernando Psychological Medicine University of Auckland Auckland District Health Board www.insomniaspecialist.co.nz www.calm.auckland.ac.nz Topics How to diagnose How to manage
More informationSouth London and the Maudsley NHS Foundation Trust Medicines Formulary
South London and the Maudsley NHS Foundation Trust Medicines Formulary Medicine Formulations Restrictions Additional Information / Related NICE Technology Appraisal 4.1 Hypnotics and anxiolytics 4.1.1
More informationNeuropathic Pain Treatment Guidelines
Neuropathic Pain Treatment Guidelines Background Pain is an unpleasant sensory and emotional experience that can have a significant impact on a person s quality of life, general health, psychological health,
More informationANTIDEPRESSANTS IN USE IN CLINICAL PRACTICE
Medicinska naklada - Zagreb, Croatia Conference paper ANTIDEPRESSANTS IN USE IN CLINICAL PRACTICE Mark Agius 1 & Hannah Bonnici 2 1 Clare College, University of Cambridge, Cambridge, UK 2 Hospital Pharmacy
More informationClinical guideline Published: 28 October 2009 nice.org.uk/guidance/cg90
Depression in adults: recognition and management Clinical guideline Published: 28 October 2009 nice.org.uk/guidance/cg90 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 12 June 2013 SEROPLEX 5 mg, film-coated tablet B/14 (CIP: 3400936428973) B/28 (CIP: 3400935993519) SEROPLEX 10 mg,
More informationTREATING MAJOR DEPRESSIVE DISORDER
TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.
More informationPregabalin Prescribing in Primary Care Audit Results 2012/13
Executive summary Pregabalin Prescribing in Primary Care Audit Results 2012/13 Pregabalin is extensively used across Aneurin Bevan Health Board (ABHB). It is the second highest medicine in terms of primary
More informationClinical guideline Published: 28 October 2009 nice.org.uk/guidance/cg90
Depression in adults: recognition and management Clinical guideline Published: 28 October 2009 nice.org.uk/guidance/cg90 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationEffective Health Care
Number 7 Effective Health Care Comparative Effectiveness of Second- Generation Antidepressants in the Pharmacologic Treatment of Adult Depression Executive Summary Background Depressive disorders such
More information90 dosage units per 90 days OR. Extended-release Formulations Ultram ER 90 dosage units per 90 days OR
Pre - PA Allowance 12 years of age or older Quantity Immediate-release Formulation Ultracet 720 dosage units per 90 days OR Ultram 720 dosage units per 90 days Extended-release Formulations Ultram ER 90
More informationHow to treat depression with medication: Some rules of thumb
How to treat depression with medication: Some rules of thumb R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon. Consultant Psychiatrist Regional
More information11. Psychopharmacological Intervention
11. Psychopharmacological Intervention 11.1 Goals of Psychopharmacology The goal of psychopharmacology is to ensure that patients with more severe forms of depression and those who fail to benefit adequately
More informationOXYCODONE IR (oxycodone)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Oxycodone hydrochloride, a pure opioid agonist, is used in the treatment of moderate to severe pain (1-2). The precise mechanism of action is unknown; however,
More informationAtomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD)
Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Section 1: Shared Care arrangements and responsibilities Section 1.1 Agreement to transfer of prescribing
More informationPSYCHIATRIC MANAGEMENT IN PRIMARY CARE. Dr Fayyaz Khan MBBS, MRCPsych, MSc Consultant Psychiatrist (Locum) Mersey Care NHS Trust
PSYCHIATRIC MANAGEMENT IN PRIMARY CARE Dr Fayyaz Khan MBBS, MRCPsych, MSc Consultant Psychiatrist (Locum) Mersey Care NHS Trust Areas to cover Mood Disorders Anxiety Disorders Miscellaneous Conditions
More informationFamily Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University
APPROACH TO DEPRESSION IN PRIMARY CARE Family Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University DISCLOSURE Speaker/Presenter Disclosure
More informationXartemis XR (oxycodone / acetaminophen extended release)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Xartemis XR is a combination of oxycodone and acetaminophen in a dosage formulation to deliver both immediate pain relief, in less than an hour, and extended-release
More informationPrepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.
Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D. Sources: National Institute of Mental Health (NIMH), the National Alliance on Mental Illness (NAMI), and from the American Psychological Association
More informationVolume 4; Number 20 November 2010
Volume 4; Number 20 November 2010 What s new this month: The PACEF position on agomelatine (Valdoxan), a new antidepressant, has been reviewed. Agomelatine (Valdoxan) remains RED. All prescribing should
More informationDepression in adults: treatment and management
Depression in adults: treatment and management NICE guideline: short version Draft for consultation, July 0 This guideline covers identifying, treating and managing depression in people aged and over.
More informationObjectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS
MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS Jon-Paul Khoo What is treatment resistance really? Database review 328 consecutive non-remitted MDD patients referred for private
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationRATIONALE FOR INCLUSION IN PA PROGRAM
RATIONALE FOR INCLUSION IN PA PROGRAM Background Methadone hydrochloride is a long-acting opioid agonist at mu-opioid receptors that is used to manage pain that requires long-term, daily opioid treatment
More informationMedication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford
Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Step 3: GAD with marked functional impairment or that has not improved after step 2 interventionsentions bring together everything NICE says on a topic in an interactive flowchart. are interactive and
More informationAnswer ALL questions. For each question, there is ONE correct answer. Use the answer grid provided for ALL your answers.
CLINICAL THERAPEUTICS 7: PSYCHIATRY PHA-MHBY Time allowed: 2 hours UNIVERSITY OF EAST ANGLIA School of Pharmacy Main Series UG Examination 2013-2014 Part ONE Answer ALL questions. For each question, there
More informationAnnex I. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) Scientific conclusions Taking into account the PRAC Assessment Report on the PSUR(s) for granisetron
More informationMORPHINE IR DRUG CLASS Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone)
Pre - PA Allowance Tablets & Suppositories Morphine sulfate tablets Morphine sulfate suppositories Oxymorphone tablets Hydromorphone tablets Hydromorphone suppositories 360 tablets per 90 days OR 360 suppositories
More informationOptimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE
Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Chan-Hyung Kim, MD Severance Mental Health Hospital Institute of Behavioral Science in Medicine Diagnostic Criteria Pyramid Etiologic Pathophysiologic
More informationAmendments to recommendations concerning venlafaxine
Amendments to recommendations concerning venlafaxine On 31 May 2006 the MHRA issued revised prescribing advice for venlafaxine*. This amendment brings the guideline into line with the new advice but does
More informationBELBUCA (buprenorphine buccal film)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Belbuca is indicated for the management of chronic pain severe enough to require daily, aroundthe-clock, long-acting opioid treatment for which alternative
More informationGeneralized Anxiety Disorder ( DSM -IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6
Generalized Anxiety Disorder ( DSM -IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control.
More informationInformation leaflet for primary care: Agomelatine
Information leaflet for primary care: Agomelatine Background information Agomelatine is an antidepressant indicated for the treatment of major depressive episodes in adults. Agomelatine is a melatonin
More informationDepression in Late Life
Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression
More informationBRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S.
BRIEF ANTIDEPRESSANT OVERVIEW Casey Gallimore, Pharm.D., M.S. Antidepressant Medication Classes First Generation Tricyclic Antidepressants (TCAs) Monoamine Oxidase Inhibitors (MAOIs) Second Generation
More informationAntidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder
updated 2012 Antidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder Q10: Are antidepressants (Tricyclic antidepressants
More informationElectronic Web Appendix; clinical codes for each outcome measure
Electronic Web Appendix; clinical codes for each outcome measure Table 1 Clinical codes for the diagnosis of depression recognised by the UK Quality and Outcomes Framework Descriptor Clinical code [X]
More informationHYSINGLA ER (hydrocodone bitartrate) Prior authorization is not required if prescribed by an oncologist.
Pre - PA Allowance None Prior authorization is not required if prescribed by an oncologist. Prior-Approval Requirements Age 18 years of age or older Diagnosis Patient must have the following: 1. Pain,
More informationAntidepressants. BMF 83 - Antidepressants
Antidepressants BMF 83 - Antidepressants Depression is a common psychiatric disorder impacting millions of people worldwide. It is caused by an imbalance of chemicals in the brain, namely serotonin and
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 6. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationFor: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013
For: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013 This power point is only a guideline for recommendations in the treatment of psychiatric disorders. This is not comprehensive. Please
More informationPharmacists in Medication Adherence in Psychiatric Patients
Pharmacists in Medication Adherence in Psychiatric Patients Mamta Parikh, PharmD, BCPS, BCPP Assistant Professor, Clinical and Administrative Sciences Notre Dame of Maryland University School of Pharmacy
More informationJoint Formulary for Psychotropic Medication.
Joint for Psychotropic Medication. This document has been produced in collaboration with the Lancashire Commissioning Support Unit Page 1 Table of Contents Section Page Number Page 2 Definition of categories
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 1 October 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 1 October 2008 EFFEXOR SR 37.5 mg prolonged-release capsule B/30 (CIP: 346 563-3) EFFEXOR SR 75 mg prolonged-release
More informationAntidepressant Guidelines
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire West Primary Care Alliance [APC ClinDoc 037] For the latest
More informationPre - PA Allowance. Prior-Approval Requirements LEVORPHANOL TARTRATE. None
Pre - PA Allowance None Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist and/or the member has paid pharmacy claims for an oncology medication(s) in the past
More information